Intra-Cellular Therapies (ITCI) Sinks 69% as Trading Resumes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Intra-Cellular Therapies (ITCI) PT Cut to $22 at Piper Jaffray; Thinks Trial Not Drug a Failure
September 29, 2016 6:47 AM EDTPiper Jaffray analyst Charles Duncan slashed his price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $22.00 (from $57.00) after the company announced that its second P3 in schizophrenia failed to meet the primary endpoint, with 007 generating improvements in the PANSS that were over-shadowed by a higher-than-expected placebo response. The analyst maintained... More
Intra-Cellular Therapies (ITCI) PT Cut to $29 at Leerink Partners Amid ITI-007 Failure
September 29, 2016 6:38 AM EDTLeerink Partners analyst Seamus Fernandez slashed his price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $29.00 (from $95.00) but maintained an Outperform rating on the disappointing result that ITCI's leading drug candidate, ITI-007, failed to separate from placebo in the second Ph 3 schizophrenia study. Neither the 60... More
Intra-Cellular Therapies (ITCI) to Resume Trading at 4:30 PM ET
September 28, 2016 4:10 PM EDTIntra-Cellular Therapies (NASDAQ: ITCI) to Resume Trading at 4:30 PM ET
... MoreIntra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
September 28, 2016 4:03 PM EDTIntra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the... More
